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Serotonin type 3 receptors (5-HT3) are involved in learning, cognition and emotion, and have been implicated in various
psychiatric phenotypes. However, their contribution to the pathomechanism of these disorders remains elusive. Three single
nucleotide polymorphisms (SNPs) in the HTR3A and HTR3B genes (rs1062613, rs1176744 and rs3831455) have been associated
with bipolar affective disorder (BPAD) in pilot studies, and all of them are of functional relevance. We performed a European
multicenter study to conﬁrm previous results and provide further evidence for the relevance of these SNPs to the etiology of
neuropsychiatric disorders. This involved analysis of the distribution of the three SNPs among 1804 BPAD cases and 2407 healthy
controls. A meta-analysis revealed a pooled odds ratio of 0.881 (P¼0.009, 95% conﬁdence intervals¼0.802–0.968) for the non-
synonymous functional SNP HTR3B p.Y129S (rs1176744), thereby conﬁrming previous ﬁndings. In line with this, the three genome-
wide association study samples BOMA (Bonn-Mannheim)-BPAD, WTCCC (Wellcome Trust Case Control Consortium)-BPAD and
GAIN (Genetic Association Information Network)-BPAD, including 43500 patients and 5200 controls in total, showed an
overrepresentation of the p.Y129 in patients. Remarkably, the meta-analysis revealed a P-value of 0.048 (OR¼0.934, ﬁxed effect
model). We also performed expression analyses to gain further insights into the distribution of HTR3A and HTR3B mRNA in the
human brain. HTR3A and HTR3B were detected in all investigated brain tissues with the exception of the cerebellum, and large
differences in theA:B subunit ratio were observed. Interestingly, expressionoftheB subunit was most prominentinthe brain stem,
amygdalae and frontal cortex, regions of relevance to psychiatric disorders. In conclusion, the present study provides further
evidence for the presence of impaired 5-HT3 receptor function in BPAD.
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Introduction
Serotonin type 3 (5-HT3) receptors are involved in neural
processesrelated tocognitionand emotion, andantagonistsof
these receptors have been shown to be beneﬁcial in the
treatment of various psychiatric disorders. In particular,
improvement in depressive symptoms, memory and cognition
have been described in psychiatric patients.
1 Furthermore,
distinct 5-HT3 receptor variants have been implicated in the
pathophysiology of bipolar affective disorder (BPAD), schizo-
phrenia and eating disorders.
2 Functional receptors contain
ﬁve subunits of diverse composition. In humans, 5-HT3
subunits are encoded by ﬁve genes: HTR3A–E.O ft h e s e
subunits, the 5-HT3A and 5-HT3B have been characterized
most extensively. In vitro studies have shown that only the
5-HT3Asubunitiscapableofformingfunctionalhomopentameric
receptors whereas the other subunits require 5-HT3A to build
heteropentameric complexes.
3 Comparative expression ana-
lyses of all ﬁve HTR3 genes on the mRNA level, using
conventional PCR have shown that expression of the 5-HT3E
subunit is restricted to certain tissues of the gastrointestinal
tract,whereastheothersubunitsareexpressedubiquitously.
4
Early studies in the 1990s using radioligand binding revealed
5-HT3 selective binding in distinct brain regions. Different
ligand-binding densities were observed in the forebrain
regions analyzed, depending on the radioligand used; for
example, zacopride, LY278584 or granisetron.
5–8 However,
5-HT3Awastheonlyknownsubunitofthistypeofreceptorsat
that time, the complexity of the human 5-HT3 receptor system
ﬁrst became apparent during the last decade, and the
composition of native receptor subtypes remains elusive.
2
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www.nature.com/tpConsequently, the difference in binding density depending on
the applied ligand may reﬂect the existence of receptor
subtypes of differing compositions and afﬁnities.
3 Although
expressionofHTR3Ahasbeenreportedinthecerebralcortex,
amygdala,hippocampus,caudate andthalamus onthemRNA
level in humans
9,10 contradictory data exist concerning the
expression of HTR3B in the central nervous system.
11
In two pilot case–control studies, the variants HTR3A
c. 42C4T (rs1062613) and HTR3B p.Y129S (c.386A4C,
rs1176744), as well as the small deletion HTR3B
c. 104_ 102delAGA (rs3831455) were found to be asso-
ciated with BPAD.
12,13
All of these variants have been shown to exhibit functional
effects in vitro.
13–19 Furthermore, the two single nucleotide
exchanges have also been implicated in anorexia nervosa
and irritable bowel syndrome, both of which show high
comorbidity with anxiety and depression,
14,20 whereas
HTR3B p.Y129S appears to have a role in major depres-
sion.
21 In addition, HTR3A c. 42C4T has been correlated
with altered amygdala activity and increased anxiety scores in
paradigms testing emotional response in vivo.
22,23
The identiﬁcation of identical risk variants for different
psychiatricphenotypessupportsthehypothesisthatinspiteof
discriminable clinical diagnoses, these phenotypes share
some aspects of the underlying biology.
24 The aim of the
present European multicenter study was to conﬁrm the
previous association ﬁndings and provide further evidence
for the hypothesis that functional HTR3 variants are impli-
cated in the etiology of various psychiatric disorders. We
successfully replicated the association between the HTR3B
variant p.Y129S (rs1176744) and BPAD in a large European
case–control cohort consisting of 41800 cases and 2400
controls. Furthermore, we were able to conﬁrm co-expression
of both the 5-HT3A and 5-HT3B subunits in brain structures of
relevance to anxiety and depression.
Materials and methods
European patient–control samples. All protocols and
procedures were approved by the respective local Ethics
Committees. Written informed consent was obtained from all
study participants before the study participation. All patients
were assigned a lifetime diagnosis of BPAD type I or type II.
This was based on Diagnostic and Statistical Manual of
Mental Disorders-IV criteria and a consensus best-estimate
procedure, including a structured interview-I, review of
medical records, the family history method and the
Operational Criteria Checklist for Psychotic Illness OPCRIT
system. Patients were recruited from consecutive
admissions to the psychiatric inpatient units of seven
clinical centers: (A) the Central Institute of Mental Health,
Mannheim, and the Department of Psychiatry and
Psychotherapy of the University of Bonn (n¼378 patients/
768 controls); (B) Department of Psychiatry, Poznan
University of Medical Sciences, Poznan, Poland (n¼446
patients/558 controls); (C) Alexandru Obregia Clinical
Psychiatric Hospital, Bucharest, Romania (n¼237 patients/
235 controls); (D) Civil Hospital Carlos Haya, Malaga, Spain
(n¼297 patients/401 controls); (E) Russian State Medical
University, Moscow (n¼331 patients/331 controls); (F)
Psychiatric Clinic, Clinical Center of the University of
Sarajevo, Sarajevo, Bosnia-Herzegovina (n¼124 patients/
115 controls). Ethnicity was assigned to patients and controls
on the basis of self-reported ancestry at each of the seven
recruitment sites. The given numbers reﬂect the sample
sizes after quality control (sample call rate 490%). This
sample was used before for replication purposes as part of a
genome-wide association study study (replication I).
25
Independent replication data sets. To further strengthen
our association ﬁnding, rs1176744 was examined in
three independent genome-wide data sets.
25–27 First, this
study makes use of data generated for the BOMA
(Bonn-Mannheim)-BPAD case–control cohort consisting of
682 cases and 1300 controls.
25 In addition, data for two
independent, well-known BPAD studies were included. The
Wellcome Trust Case–Control Consortium BPAD study
26
makes use of a cohort of 1868 patients and 2938 controls. As
rs1176744 was not available in the set of genotyped markers
for this study, the proxy rs4938058 (r
2¼0.898) was analysed.
Finally, a sample of 987 patients and 1000 controls was
derived from the Database of Genotypes and Phenotypes
data set
28 ‘Whole Genome Association Study of Bipolar Dis-
order’ (phs000017.v3.p1).
27 Here, another proxy rs1176743
(r
2¼0.919) was used.
DNA extraction and genotyping. EDTA anti-coagulated
venous blood samples were collected from all individuals.
Lymphocyte DNA was isolated by salting-out with saturated
sodium chloride solution 4, or by the use of a Chemagic
Magnetic Separation Module I (Chemagen, Baesweiler,
Germany) according to the manufacturer’s recommendations.
Genotyping was performed using the Matrix-Assisted-
Laser-Desorption/lonization–Time-Of-Flight (MALDI-TOF)-
based MassARRAY system and iPLEX Gold assays (Seque-
nom, San Diego, CA, USA). Primer sequences and assay
conditions are obtainable upon request. Single nucleotide
polymorphisms (SNPs) raw genotype data, that is, cluster
plots, were visually assessed by two investigators. SNP and
sample call rates were 490%.
Statistical analyses. PLINK (v1.07; http://pngu.mgh.
harvard.edu/~purcell/plink/) was used for the analysis of
statistical association between the single SNPs and affection
status (trend test), and to test for deviations from Hardy-
Weinberg equilibrium. The SNPassoc package (http://www.
creal.cat/jrgonzalez/software.htm) for R was used to calcu-
late P-values, odds ratios (OR) and 95% conﬁdence intervals
(CI), assuming a log-additive inheritance model adjusted for
sex.
29 SPSS Statistics 17.0 (IBM Deutschland GmbH, Munich,
Germany) was used in the performance of a Cochran-
Maentel-Haentzel (CMH) meta-analysis to obtain pooled
estimates of the ORs across nationalities, and Breslow-Day
tests for homogeneity of the ORs. Signiﬁcant P-values were
corrected for three tests using the Bonferroni method, but are
displayed uncorrected in text and tables. For the replication
analysis in genome-wide association study data sets, a ﬁxed
effect model was used assuming an additive effect. To
assess putative false-negative results, a power calculation
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pngu.mgh.harvard.edu/~purcell/gpc/).
30
Expression analyses on the mRNA level. The total RNA
from human adult brain used in the present experiments was
either obtained commercially or was isolated from brain
tissue obtained from the German Brain Bank Brain-Net
(http://www.brain-net.net). The human fetal material was
provided by the Joint MRC Wellcome Trust Human
Developmental Biology Resource (http://www.hdbr.org).
Trizol reagent (Life Technologies, Darmstadt, Germany)
was used for the extraction of RNA, as recommended by
the manufacturer (Table 1). The experiments were approved
by the ethics committee of the University of Heidelberg.
Total RNA (100ng) served as input material in nCounter
(Nanostring, Seattle, WA, USA) analysis using a customized
codeset, as recommended by the manufacturer. In particular,
theusedcodesetsforHTR3AandHTR3Bexpressionproﬁling
among 18 other target genes are included in Table 2
(Supplementary data). Background correction and normal-
ization of data was performed as follows. In brief, for each
sample, the average þ 2 SDS of background counts
(negative controls) was calculated. For each gene for each
sample, the average þ 2 SDS was subtracted from the
counts. Expression of HTR3A (NM_000869.5) and HTR3B
(NM_006028.3) was normalized by taking the geometric
mean of the expression of the three reference genes
ADAM9 (NM_003816.2), PGK1 (NM_000291.3) and SNX17
(NM_014748.2) into account.
31
Results
In the current case–control study, 41800 cases and 2400
controlsfromsixEuropeancountrieswereanalyzed(Table2).
Genotype call rates were at least 97.6% for each SNP, and
none of the tested variants deviated from Hardy-Weinberg
equilibrium in patients or controls (data not shown).
For HTR3B p.Y129S (c.386A4C, rs1176744) a pooled
odds ratio (OR) of 0.881 (95% CI¼0.802–0.968) was
determined in a CMH analysis, yielding a signiﬁcant P-value
of 0.009 (Figure 1). This was because of an overrepresenta-
tion of the p.Y129 allele in BPAD patients. A Breslow-Day test
for homogeneity of ORs revealed no signiﬁcant deviation
(P¼0.076). In the national subgroups, signiﬁcant P-values
were detected for the Polish and Spanish cohorts in a
Cochran-Armitage trend test, under the assumption of a
log-additive inheritance model (Table 3). The P-values
Table 1 Brain tissue used for total RNA extraction followed by nCounter analysis
RNA Donor information
Number Race Gender Age COD Company
Brain Pool of 3 Caucasian Male 23 Cardiac arrest FirstChoice Human Total RNA
Survey Panel
Caucasian Male 81 Congestive heart
failure
Caucasian Female 78 Congestive heart
failure
Frontal cortex Single Caucasian Male 23 Cardiac Arrest FirstChoice Human Total RNA
Thalamus Single n.a. Female 71 Chronic obstructive
pulmonary disease
BioChain Total RNA
Right
cerebellum
Single n.a. Male 82 Aortic stenosis BioChain Total RNA
Hippocampus Single Asian Male 27 Accident BioChain Total RNA
Spinal cord Single Asian Male 27 Accident BioChain Total RNA
Striatum Single n.a. Male 20 n.a. Stratagene MVP Total RNA
Insula Pool of 15 Caucasian Male/
female
20–68 Sudden death Clontech Total RNA
Amygdala Pool of 2 Caucasian Female 21 Pneumonia BrainNet Germany
Caucasian Male 68 Cardiac arrest BrainNet Germany
Brain stem Pool of 2 Caucasian Female 21 Pneumonia BrainNet Germany
Caucasian Male 68 Cardiac arrest BrainNet Germany
Fetal brain Single n.a. n.a. F2 Induced abortion MRC Wellcome Trust
Human Developmental Biology
Resource
Fetal
cerebellum
Single n.a. n.a. F2 Induced abortion MRC Wellcome Trust
Human Developmental Biology
Resource
Fetal
thalamus
Single n.a. n.a. F2 Induced abortion MRC Wellcome Trust
Human Developmental Biology
Resource
Abbreviation: COD, cause of death.
Table 2 Number of genotyped BPAD cases and controls, totals and according
to nationality
Nationality N (cases) N (controls) N (Cases +
controls)
Bosnian-Herzegovinan 124 115 239
German 378 768 1146
Polish 446 558 1004
Romanian 237 233 471
Russian 331 333 663
Spanish 298 400 698
Total 1814 2407 4221
Abbreviation: BPAD, bipolar affective disorder.
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Table 3. In view of statistical power issues, the national
subgroups were not separated stratiﬁed according to sex.
However, CMH analyses showed a clear sex-speciﬁc
association. Although there was no association with the
p.Y129S variant in females, the analysis of male patients vs
controls resulted in a P-value of 0.0002 (OR¼0.794,
CI¼0.684–0.921) (Figure 1).
In a further step to strengthen our association ﬁnding,
rs1176744 (or its proxies) was examined in the three
independent genome-wide data sets BOMA-BPAD, WTCCC
(Wellcome Trust Case Control Consortium)-BPAD and
Genetic Association Information Network-BPAD, including
43500 patients and 5200 controls in total.
25–27 Remarkably,
in all three samples, the p.Y129 allele was overrepresented
in patients, and a ﬁnal meta-analysis revealed a P-value of
0.048 (OR¼0.934, ﬁxed effects model), thereby conﬁrming
the original association with BPAD.
No signiﬁcant results were obtained for the cis-regulatory
variants HTR3A c. 42C4T (rs1062613) and HTR3B c. 104
 102delAGA (rs3831455) in the CMH analyses (data not
shown). The former was found to be associated in the Polish
subgroup (P(log-additive) ¼ 0.002, OR¼0.71, 95% CI¼
0.57–0.89), and nominally associated in the Bosnian-
Herzegovinian subgroup (P(log-additive)¼0.025, OR¼
1.72, 95% CI¼1.05–2.80). However, the calculated ORs
point to different risk alleles.
To address the possibility of false-negative ﬁndings, a
powercalculationwasperformedassumingthecalculatedOR
of the HTR3B p.Y129S CMH analysis and a population risk
of 2%. This yielded a statistical power of 66% for HTR3A
c. 42C4T and of 47% for HTR3B c. 104_ 102delAGA.
Figure 1 Odds ratio (OR) distribution across nationalities for HTR3B p.Y129S (rs1176744). The number of patients and healthy controls for each country is shown along
with the respective OR and 95% conﬁdence intervals (CI). The common P-value, OR and 95% CI (bold numbers) were determined using a Cochran-Maentel-Haenszel test.
A Breslow-Day test was performed to test for homogeneity of ORs.
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expression levels directly without any further enzymatic
modiﬁcation of the sample,
32 we detected relative expres-
sion of both subunit genes on the transcript level, that is,
HTR3A and HTR3B in total RNA samples from different
human brain regions (Figure 2). In the tested adult brain
tissues, relative code counts of the A and B subunits (code
count B/code count A ratio) was found in the following
descending order: brain stem (130), amygdala (30), frontal
cortex (15), striatum (4.7), insula (4), thalamus (2.2) and
hippocampus (1.6). The only tested tissue to show nearly
equal code counts in adult tissue was the spinal cord (0.9).
No expression was found in adult cerebellum. In the tested
fetal tissues, the B:A code count ratio was 41 in the thalamus
and 0.16 in hindbrain whereas in the cerebellum B was not
detectableatall.Interestingly,therelativeexpressionlevelof
the B subunit was besides the brain stem highest in the
amygdala and frontal cortex, that is, regions in which
disturbances may lead to the manifestation of psychiatric
disorders.
Discussion
In the present study, the HTR3B p. Y129S variant was
successfully replicated overall, and showed signiﬁcant asso-
ciations in the CMH analysis and in the Polish and Spanish
subgroups. The p.129Y allele was overrepresented in
patients, and this ﬁnding is consistent with previous associa-
tion data for BPAD, anorexia nervosa and major depres-
sion.
12,20,21 On a functional level, homozygous 5-HT3AB
p.129Y receptors displayed a decreased 5-HT maximum
response, caused by a sevenfold decrease in single channel
mean open time, compared with homozygous 5-HT3AB
p.129S receptors.
16,19 This striking difference may result in
a disease-relevant change in 5-HT3 receptor signaling.
The contribution of 5-HT3 receptors to the etiology of
psychiatric disorders is underlined by data from animal
studies. Behavioral tests in primates and rodents revealed
anxiolytic effects of 5-HT3 antagonists secondary to blockage
of the limbic hyperactivity response.
33 This is consistent with
studies of 5-HT3A knockout mice, which show reduced
Table 3 Genotype counts and association statistics
SNP Study subgroup Genotypes (and frequencies) cases P-value Trend
test, d.f.¼1
P-value (OR, (95% CI))
Genotypes (and frequencies) controls Log additive, adjusted
according to sex
rs1062613 CC (%) CT (%) TT (%)
Bosnia-Herzegovina 70 (58) 44 (37) 6 (5)
81 (71) 30 (27) 2 (2) 0.073 0.025 (1.72, (1.06–2.80))
Germany 224 (62) 124 (34) 15 (4)
469 (62) 260 (34) 30 (4) 0.99 0.937 (0.99, (0.79–1.24))
Poland 306 (70) 114 (26) 16 (4)
335 (61) 180 (33) 33 (6) 0.01 0.002 (0.71, (0.57–0.89))
Romania 144 (63) 70 (31) 13 (6)
142 (65) 69 (31) 8 (4) 0.579 0.524 (1.11, (0.8–1.53))
Russia 205 (63) 109 (33) 11 (3)
205 (63) 105 (32) 14 (4) 0.808 0.865 (0.98, (0.74–1.28))
Spain 167 (57) 107 (36) 20 (7)
207 (52) 157 (39) 34 (9) 0.416 0.190 (0.85, (0.67–1.08))
rs3831455 ins/ins (%) ins/del (%) del/del (%)
Bosnia-Herzegovina 97 (81) 21 (18) 2 (2) 0.312 0.195 (0.69, (0.40–1.21))
82 (73) 29 (26) 2 (2)
Germany 278 (77) 80 (22) 5 (1) 0.702 0.477 (1.11, (0.84–1.47))
594 (78) 158 (21) 7 (1)
Poland 328 (75) 99 (22) 9 (2) 0.221 0.099 (1.26, (0.96–1.65))
430 (79) 107 (20) 6 (1)
Romania 174 (77) 46 (20) 6 (3) 0.591 0.812 (0.95, (0.65–1.40))
162 (75) 52 (24) 3 (1)
Russia 252 (78) 63 (19) 9 (3) 0.204 0.239 (1.22, (0.87–1.70))
261 (81) 59 (18) 4 (1)
Spain 245 (83) 47 (16) 3 (1) 0.597 0.295 (0.83, (0.58–1.18))
318 (80) 75 (19) 5 (1)
rs1176744 AA (%) AC (%) CC (%)
Bosnia-Herzegovina 54 (44) 57 (46) 13 (11) 0.3 0.152 (1.34, (0.90–1.99))
61 (54) 44 (39) 9 (8)
Germany 191 (51) 152 (41) 31 (8) 0.321 0.178 (0.87, (0.72–1.06))
355 (47) 335 (44) 73 (10)
Poland 235 (54) 157 (36) 45 (10) 0.017 0.037 (0.82, (0.68–0.99))
249 (45) 245 (44) 58 (11)
Romania 120 (51) 93 (40) 22 (9) 0.367 0.857 (0.97, (0.73–1.30))
110 (48) 105 (46) 16 (7)
Russia 154 (47) 140 (43) 34 (10) 0.889 0.950 (1.01, (0.80–1.27))
151 (45) 154 (46) 28 (8)
Spain 128 (43) 136 (46) 32 (11) 0.013 0.005 (0.73, (0.59–0.91))
142 (36) 181 (46) 73 (18)
Abbreviations: CI, conﬁdence interval; d.f., degrees of freedom; OR, odds ratio; SNP, single nucleotide polymorphism.
Frequencies (%) were rounded off to the nearest whole number. P-values are displayed in bold if withstanding Bonferroni correction, nominally signiﬁcant P-values
are shown in italics.
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34 Further investigation of these knock-
out mice led to the conclusion that the regulation of
depression- and anxiety-related behaviors by the 5-HT3A
subunit differs between males and females.
35
Theeffectof5-HT3Aonanxietycontrolhasbeenreportedto
be mediated by regulation of hypothalamic-pituitary-adrenal
responses to acute stress.
36 This suggests a potential
interaction between 5-HT3A and corticotropin-releasing hor-
mone in the amygdala. Sex differences in 5-HT3A- receptor-
dependent hypothalamic-pituitary-adrenal responses in
chronically stressed mice have also been reported.
36
The observed association in males in the present study is in
line with animal data.
35 A feasible hypothesis is that 5-HT3
receptors are involved in the modulation of anxiety-related
behaviors, which are important phenotypes in the sympto-
matic spectrum of BPAD.
Moreover, 5-HT3 antagonist treatment in humans has
been shown to be an effective treatment for anxiety and
depression.
37,38
A further aim of the present study was to gain insights into
5-HT3 receptor subunit expression in the human brain. As
outlined above, the expression of 5-HT3 receptors has mainly
been analyzed using 5-HT3-binding site-selective com-
pounds.
5–8 Our data are consistent with these early human
brain ligand-binding data. Our results indicate that the
expression of both subunits appears to switch during
development. This switch in the 5-HT3A and 5-HT3B receptor
ratio is interesting, since recent studies have described the
relevance of 5-HT3 receptors to neuronal plasticity in the
cortex. Application of the 5-HT3 receptor antagonist tropise-
tron led to a speciﬁc blockade of the 5-HT3 response on Cajal-
Retzius cells in mice, and 5-HT3 receptors were shown to be
involved in postnatal dendritic maturation and neuronal
plasticity in the cortex.
39 In consequence, changes in the
brain organization of variant carriers are conceivable.
Disturbed column architecture of the cortex has indeed been
reported in the brains of psychiatric patients.
40 Whether or not
this is related to polymorphic changes in HTR3 genes still
awaits investigation.
Future studies are warranted to determine the functional
and structural consequences of receptor polymorphisms
in vivo. Recent studies by the present authors, using
transiently transfected human cell lines, showed that the ratio
between the subunits A and B determines receptor composi-
tion and consequently the formation of homomeric and
heteromeric B subunits.
19,41
We were able to conﬁrm co-expression of both 5-HT3
subunits in brain regions involved in memory, cognition and
anxiety control, that is, the frontal cortex, the hippocampus
and the amygdala, respectively. Murine studies have shown
that 70–80% of 5-HT3 receptors are located presynaptically
and are associated with axons and nerve terminals, with the
exception of those in the hippocampus, which are mainly
postsynaptic and located in somatodendritic regions.
42 The
high presynaptic expression of 5-HT3 receptors is consistent
with their physiological role in neurotransmitter release
(dopamine, cholecystokinin, glutamate, acetylcholine and
gamma-aminobutyric acid (GABA)).
43 Accordingly, both the
excitatory and the inhibitory effects of 5-HT3R activation are
mediated by activation of excitatory or inhibitory interneur-
ons.
44 For example, 5-HT3R activation of GABAergic
interneurons innervating the amygdala is thought to exert
an inhibitory inﬂuence on amygdala activity, whereas the
activation of excitatory glutamatergic interneurons is hy-
pothesized to have the opposite effect.
44 However, the
situation in humans remains unknown. To date, systematic
analysis has been hampered by the lack of speciﬁc
antibodies.
Taken together, our results support the hypothesis that the
HTR3B p.Y129S variant is implicated in BPAD, and the
association could be replicated in a meta-analysis utilizing
large published genome-wide association study data sets.
Futurestudiesarewarrantedtoinvestigateapossibleeffectof
this common genetic variant on further relevant neuropsy-
chiatric phenotypes such as anxiety, stress response and
depressive episodes, as well as memory and cognition. In
doing so, possible gender-speciﬁc effects should also be
taken into account.
In contrast to the HTR3B variant p.Y129S, the variants
HTR3A c. 42C4T (rs1062613) and HTR3B c. 104
 102delAGA (rs3831455) were not replicated in our study
overall. In fact, for the HTR3A variant, association analysis in
the national subgroups generated contradictory results.
Whereas pilot studies into BPAD, irritable bowel syndrome
and eating disorders have implicated the less frequent T allele
in the development of the disease phenotypes,
14,20,45 in the
present study the C allele occurred more often in Polish
patients. Although the nominally signiﬁcant association in the
subgroup from Bosnia-Herzegovina replicated earlier
results (P(log-additive) ¼ 0.025), the sample was small and
probably lacked statistical power to detect true positives.
Hence, our study does not support the hypothesis that
HTR3A c. 42C4T SNP or the small deletion HTR3B
c. 104_ 102delAGA are involved in the etiology of BPAD.
Nevertheless, the retrospective power calculation for the
whole sample indicates that our study cohort may have been
too small to detect minor effects.
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Figure 2 HTR3A and HTR3B mRNA expression proﬁling. mRNA levels
were directly quantiﬁed using the nCounter technology. (a) Comparison of adult
and fetal brain overall; (b) fetal brain areas and (c) adult brain regions. Abbreviations:
CB, cerebellum; HB, hind brain; HIP, hippocampus; THA, thalamus; INS,insula; STRI,
striatum; SC, spinal cord; AMY, amygdala; BS, brain stem; FC, frontal cortex.
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Translational PsychiatryIn conclusion, the present study replicated the functional
HTR3B variant p.Y129S as a predisposing factor for BPAD.
Future studies should investigatethe precise role of HTR3B in
this disorder. The sex speciﬁcity of the association points to a
putative function in the hypothalamic-pituitary-adrenal axis,
resultinginanxiety-relatedphenotypes.Interestingly, differing
code-count ratios of the A and B subunits were found in
variousadultandfetalbrainregions,suggestingdifferencesin
receptor function and composition in the developing, com-
pared with the adult brain.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements. We thank Carolin Wohlfarth for her excellent
technical assistance and Claudia Durand and Christine Schma ¨l for fruitful
discussions. We also acknowledge the German Brain Bank Brain-Net (http://
www.brain-net.net) for providing amygdala and frontal cortex brain tissue. The
‘Brain-Net’ issupportedbytheGermanFederalMinistryof EducationandResearch
(BMBF). The human fetal materials were obtained from the Joint MRC Wellcome
Trust Human Developmental Biology Resource (http://www.hdbr.org) at the IHG,
Newcastle Upon Tyne, UK, with funding from Grants G0700089 and GR082557.
The study was funded by the Medical Faculty of the University of Heidelberg. MR,
SC and MMN were supported by the German Federal Ministry of Education
and Research (BMBF), within the context of the National Genome Research
Network 2 (NGFN-2), the National Genome Research Network plus (NGFNplus)
and the Integrated Genome Research Network (IG) MooDS (Grant 01GS08144 to
SC and MMN, Grant 01GS08147 to MR). JS was supported by the German
Research Foundation (GRK 793). This study makes use of data generated by the
Wellcome Trust Case–Control Consortium.
26 A full list of the investigators who
contributed to the generation of the data is available from http://www.wtccc.org.uk.
Funding for the project was provided by the Wellcome Trust under award 076113
and 085475.
1. Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: a
probable neuronal target? J Psychopharmacol 2010; 24: 455–469.
2. Niesler B. 5-HT(3) receptors: potential of individual isoforms for personalised therapy. Curr
Opin Pharmacol 2011; 11: 81–86.
3. Walstab J, Rappold G, Niesler B. 5-HT(3) receptors: role in disease and target of drugs.
Pharmacol Ther 2010; 128: 146–169.
4. Niesler B, Frank B, Kapeller J, Rappold GA. Cloning, physical mapping and expression
analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E.
Gene 2003; 310: 101–111.
5. Abi-Dargham A, Laruelle M, Wong DT, Robertson DW, Weinberger DR, Kleinman JE.
Pharmacological and regional characterization of [3H]LY278584 binding sites in human
brain. J Neurochem 1993; 60: 730–737.
6. Barnes JM, Barnes NM, Costall B, Ironside JW, Naylor RJ. Identiﬁcation and
characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue.
J Neurochem 1989; 53: 1787–1793.
7. Bufton KE, Steward LJ, Barber PC, Barnes NM. Distribution and characterization of the
[3H]granisetron-labelled 5-HT3 receptor in the human forebrain. Neuropharmacology
1993; 32: 1325–1331.
8. Parker RM, Barnes JM, Ge J, Barber PC, Barnes NM. Autoradiographic distribution
of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J Neurol Sci 1996; 144:
119–127.
9. Belelli D, Balcarek JM, Hope AG, Peters JA, Lambert JJ, Blackburn TP. Cloning and
functional expression of a human 5-hydroxytryptamine type 3AS receptor subunit. Mol
Pharmacol 1995; 48: 1054–1062.
10. Miyake A, Mochizuki S, Takemoto Y, Akuzawa S. Molecular cloning of human 5-
hydroxytryptamine3 receptor: heterogeneity in distribution and function among species.
Mol Pharmacol 1995; 48: 407–416.
11. Jensen AA, Davies PA, Brauner-Osborne H, Krzywkowski K. 3B but which 3B and that’s
just one of the questions: the heterogeneity of human 5-HT3 receptors. Trends Pharmacol
Sci 2008; 29: 437–444.
12. Frank B, Niesler B, Nothen MM, Neidt H, Propping P, Bondy B et al. Investigation of the
human serotonin receptor gene HTR3B in bipolar affective and schizophrenic patients. Am
J Med Genet B Neuropsychiatr Genet 2004; 131B: 1–5.
13. Niesler B, Weiss B, Fischer C, Nothen MM, Propping P, Bondy B et al. Serotonin receptor
gene HTR3A variants in schizophrenic and bipolar affective patients. Pharmacogenetics
2001; 11: 21–27.
14. Kapeller J, Houghton LA, Monnikes H, Walstab J, Moller D, Bonisch H et al. First evidence
for an association of a functional variant in the microRNA-510 target site of the serotonin
receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Hum Mol
Genet 2008; 17: 2967–2977.
15. Ji X, Takahashi N, Branko A, Ishihara R, Nagai T, Mouri A et al. An association
between serotonin receptor 3B gene (HTR3B) and treatment-resistant schizophrenia
(TRS) in a Japanese population. Nagoya J Med Sci 2008; 70: 11–17.
16. Krzywkowski K, Davies PA, Feinberg-Zadek PL, Brauner-Osborne H, Jensen AA. High-
frequency HTR3B variant associated with major depression dramatically augments
the signaling of the human 5-HT3AB receptor. Proc Natl Acad Sci USA 2008; 105:
722–727.
17. Krzywkowski K, Davies PA, Irving AJ, Brauner-Osborne H, Jensen AA. Characterization of
the effects of four HTR3B polymorphisms on human 5-HT3AB receptor expression and
signalling. Pharmacogenet Genomics 2008; 18: 1027–1040.
18. Meineke C, Tzvetkov MV, Bokelmann K, Oetjen E, Hirsch-Ernst K, Kaiser R et al.
Functional characterization of a -100_-102delAAG deletion-insertion polymorphism
in the promoter region of the HTR3B gene. Pharmacogenet Genomics 2008; 18:
219–230.
19. Walstab J, Hammer C, Bonisch H, Rappold G, Niesler B. Naturally occurringvariants in the
HTR3B gene signiﬁcantlyalter properties ofhuman heteromeric 5-hydroxytryptamine-3A/B
receptors. Pharmacogenet Genomics 2008; 18: 793–802.
20. Hammer C, Kapeller J, Endele M, Fischer C, Hebebrand J, Hinney A et al. Functional
variants oftheserotonin receptor type 3A and Bgene are associated with eating disorders.
Pharmacogenet Genomics 2009; 19: 790–799.
21. Yamada K, Hattori E, Iwayama Y, Ohnishi T, Ohba H, Toyota T et al. Distinguishable
haplotype blocks in the HTR3A and HTR3B region in the Japanese reveal
evidence of association of HTR3B with female major depression. Biol Psychiatry 2006;
60: 192–201.
22. Iidaka T, Ozaki N, Matsumoto A, Nogawa J, Kinoshita Y, Suzuki T etal. A variant C178T in
the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in
the human amygdala. J Neurosci 2005; 25: 6460–6466.
23. Kilpatrick LA, Labus JS, Coveleskie K, Hammer C, Rappold G, Tillisch K et al. The HTR3A
polymorphism c. -42C4T is associated with amygdala responsiveness in patients with
irritable bowel syndrome. Gastroenterology 2011; 140: 1943–1951.
24. Craddock N, O’Donovan MC, Owen MJ. Genes for schizophrenia and bipolar disorder?
Implications for psychiatric nosology. Schizophr Bull 2006; 32: 9–16.
25. Cichon S, Muhleisen TW, Degenhardt FA, Mattheisen M, Miro X, Strohmaier J et al.
Genome-wide association study identiﬁes genetic variation in neurocan as a susceptibility
factor for bipolar disorder. Am J Hum Genet 2011; 88: 372–381.
26. Wellcome Trust Case Control Consortium. Genome-wide association study of
14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:
661–678.
27. Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W et al. Genome-wide
association study of bipolar disorder in European American and African American
individuals. Mol Psychiatry 2009; 14: 755–763.
28. Mailman MD, Feolo M, Jin Y, Kimura M, Tryka K, Bagoutdinov R et al. The NCBI dbGaP
database of genotypes and phenotypes. Nat Genet 2007; 39: 1181–1186.
29. Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X et al. SNPassoc:
an R package to perform whole genome association studies. Bioinformatics 2007; 23:
644–645.
30. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage
and association genetic mapping studies of complex traits. Bioinformatics 2003; 19:
149–150.
31. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate
normalization of real-time quantitative RT-PCR data by geometric averaging of multiple
internal control genes. Genome Biol 2002; 3: RESEARCH0034.
32. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL et al. Direct
multiplexed measurementofgene expressionwith color-coded probe pairs.Nat Biotechnol
2008; 26: 317–325.
33. Costall B, Naylor RJ, Tyers MB. The psychopharmacology of 5-HT3 receptors. Pharmacol
Ther 1990; 47: 181–202.
34. Kelley SP, Bratt AM, Hodge CW. Targeted gene deletion of the 5-HT3A receptor subunit
produces an anxiolytic phenotype in mice. Eur J Pharmacol 2003; 461: 19–25.
35. Bhatnagar S, Nowak N, Babich L, Bok L. Deletion of the 5-HT3 receptor differentially
affects behavior of males and females in the Porsolt forced swim and defensive withdrawal
tests. Behav Brain Res 2004; 153: 527–535.
36. BhatnagarS,ViningC.Pituitary-adrenalactivity inacute andchronicallystressedmaleand
female mice lacking the 5-HT-3A receptor. Stress 2004; 7: 251–256.
37. Lecrubier Y, Puech AJ, Azcona A, Bailey PE, Lataste X. A randomized double-blind
placebo-controlled study of tropisetron in the treatment of outpatients with generalized
anxiety disorder. Psychopharmacology (Berl) 1993; 112: 129–133.
38. Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment
of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003; 64:
1025–1030.
5-HT3 receptors in bipolar affective disorder
C Hammer et al
7
Translational Psychiatry39. Chameau P,IntaD,VitalisT,Monyer H,WadmanWJ, vanHooftJA.The N-terminalregion
of reelin regulates postnatal dendritic maturation of cortical pyramidal neurons. Proc Natl
Acad Sci USA 2009; 106: 7227–7232.
40. BuxhoevedenDP,CasanovaMF.Theminicolumnhypothesisinneuroscience.Brain2002;
125(Part 5): 935–951.
41. Walstab J, Hammer C, Lasitschka F, Moller D, Connolly CN, Rappold G et al. RIC-3
exclusively enhances the surface expression of human homomeric 5-hydroxytryptamine
type 3A (5-HT3A) receptors despite direct interactions with 5-HT3A, -C, -D, and -E
subunits. J Biol Chem 2010; 285: 26956–26965.
42. Miquel MC, Emerit MB, Nosjean A, Simon A, Rumajogee P, Brisorgueil MJ et al.
Differential subcellular localization of the 5-HT3-As receptor subunit in the rat central
nervous system. Eur J Neurosci 2002; 15: 449–457.
43. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res 2008; 195:
198–213.
44. Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT3 receptor–the relationship
between structure and function. Neuropharmacology 2009; 56: 273–284.
45. Niesler B, Flohr T, Nothen MM, Fischer C, Rietschel M, Franzek E et al. Association
between the 50 UTR variant C178T of the serotonin receptor gene HTR3A and bipolar
affective disorder. Pharmacogenetics 2001; 11: 471–475.
Translational Psychiatry is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-Noncommercial-No
DerivativeWorks3.0Unported License. To viewacopyofthis license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
5-HT3 receptors in bipolar affective disorder
C Hammer et al
8
Translational Psychiatry